Analysis of the chemotherapy effect of albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide on breast cancer and the effects of PCR, ORR, and CBR.
{"title":"Analysis of the chemotherapy effect of albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide on breast cancer and the effects of PCR, ORR, and CBR.","authors":"Youzhong Liu, Ke Gong, Songlin Yuan, Yong Xu","doi":"10.12669/pjms.41.3.9861","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To explore the chemotherapy effect of albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide on breast cancer and the effects of PCR, ORR and CBR.</p><p><strong>Methods: </strong>This was a retrospective study. During the period from January 2022 to December 2023, ninety patients with breast cancer who were treated in The First People's Hospital of Changde City were included as the research objects. Based on the principle of randomized control, the above patients were divided into the control group (45 cases, treated with pirarubicin and cyclophosphamide) and the observation group (45 cases, treated with albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide) by the random number table. Compared the chemotherapy effect and safety of the two groups.</p><p><strong>Results: </strong>After treatment, the PCR, ORR and CBR of the observation group were higher than those of the control group, while the levels of CA152, CA125, TPS, HER-2, Ki-67 and EGFR were lower than those of the control group, and the differences were statistically significant (<i>P</i><0.05). The incidence of adverse reactions was 33.33% (15/45), which was slightly higher than that of 28.89% (13/45) in the control group, the difference was not statistically significant (<i>P</i>>0.05).</p><p><strong>Conclusion: </strong>Albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide is a safe regimen that can further enhance the effect of neoadjuvant chemotherapy in the treatment of breast cancer, and it has a certain value for dissemination in the treatment of breast cancer can further enhance the effect of neoadjuvant chemotherapy in patients, which is of certain value for clinical promotion.</p>","PeriodicalId":19958,"journal":{"name":"Pakistan Journal of Medical Sciences","volume":"41 3","pages":"769-773"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911746/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12669/pjms.41.3.9861","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To explore the chemotherapy effect of albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide on breast cancer and the effects of PCR, ORR and CBR.
Methods: This was a retrospective study. During the period from January 2022 to December 2023, ninety patients with breast cancer who were treated in The First People's Hospital of Changde City were included as the research objects. Based on the principle of randomized control, the above patients were divided into the control group (45 cases, treated with pirarubicin and cyclophosphamide) and the observation group (45 cases, treated with albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide) by the random number table. Compared the chemotherapy effect and safety of the two groups.
Results: After treatment, the PCR, ORR and CBR of the observation group were higher than those of the control group, while the levels of CA152, CA125, TPS, HER-2, Ki-67 and EGFR were lower than those of the control group, and the differences were statistically significant (P<0.05). The incidence of adverse reactions was 33.33% (15/45), which was slightly higher than that of 28.89% (13/45) in the control group, the difference was not statistically significant (P>0.05).
Conclusion: Albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide is a safe regimen that can further enhance the effect of neoadjuvant chemotherapy in the treatment of breast cancer, and it has a certain value for dissemination in the treatment of breast cancer can further enhance the effect of neoadjuvant chemotherapy in patients, which is of certain value for clinical promotion.
期刊介绍：
It is a peer reviewed medical journal published regularly since 1984. It was previously known as quarterly "SPECIALIST" till December 31st 1999. It publishes original research articles, review articles, current practices, short communications & case reports. It attracts manuscripts not only from within Pakistan but also from over fifty countries from abroad.
Copies of PJMS are sent to all the import medical libraries all over Pakistan and overseas particularly in South East Asia and Asia Pacific besides WHO EMRO Region countries. Eminent members of the medical profession at home and abroad regularly contribute their write-ups, manuscripts in our publications. We pursue an independent editorial policy, which allows an opportunity to the healthcare professionals to express their views without any fear or favour. That is why many opinion makers among the medical and pharmaceutical profession use this publication to communicate their viewpoint.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
